Rockwell Medical’s (RMTI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Rockwell Medical (NASDAQ:RMTI) in a research report sent to investors on Monday, Benzinga reports. The firm currently has a $9.00 target price on the stock. HC Wainwright also issued estimates for Rockwell Medical’s Q1 2025 earnings at $0.01 EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.02 EPS and Q4 2025 earnings at $0.03 EPS.

Separately, StockNews.com raised Rockwell Medical from a sell rating to a hold rating in a research note on Wednesday, June 19th.

Rockwell Medical Stock Performance

NASDAQ:RMTI opened at $2.36 on Monday. The company has a current ratio of 2.00, a quick ratio of 1.60 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average of $1.90 and a 200-day moving average of $1.66. Rockwell Medical has a twelve month low of $1.16 and a twelve month high of $2.91. The firm has a market cap of $73.23 million, a price-to-earnings ratio of -6.56 and a beta of 1.43.

Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.05. Rockwell Medical had a negative return on equity of 6.96% and a negative net margin of 5.06%. The firm had revenue of $25.83 million for the quarter, compared to the consensus estimate of $23.01 million. During the same quarter in the previous year, the company earned ($0.18) EPS. Analysts forecast that Rockwell Medical will post -0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Rockwell Medical by 4.0% in the first quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock worth $1,856,000 after acquiring an additional 43,302 shares in the last quarter. Raymond James & Associates lifted its position in shares of Rockwell Medical by 15.9% in the 4th quarter. Raymond James & Associates now owns 220,979 shares of the company’s stock worth $418,000 after acquiring an additional 30,309 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Rockwell Medical by 877.1% during the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock worth $181,000 after acquiring an additional 92,189 shares during the period. WealthTrust Axiom LLC grew its stake in shares of Rockwell Medical by 49.3% in the 4th quarter. WealthTrust Axiom LLC now owns 31,500 shares of the company’s stock valued at $60,000 after purchasing an additional 10,400 shares during the period. Finally, SkyOak Wealth LLC grew its holdings in shares of Rockwell Medical by 47.3% in the 1st quarter. SkyOak Wealth LLC now owns 25,110 shares of the company’s stock worth $42,000 after purchasing an additional 8,065 shares during the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.